| Pegfilgrastim reduces the length of hospitalization and the time to engraftment in multiple myeloma patients treated with melphalan 200 and auto-SCT compared with filgrastim. | |
| | |
MedLine Citation:
|
PMID: 20706722 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
To reduce the duration of neutropenia after conditioning chemotherapy and autologous peripheral blood stem cell transplantation (APBSCT), granulocyte-colony stimulating factors (G-CSF) are commonly administered. We retrospectively evaluated the impact of pegfilgrastim compared to filgrastim on neutrophil engraftment, hospital stay, and supportive measures in patients with multiple myeloma after conditioning with Melphalan 200 (Mel200) followed by APBSCT. Ninety-two APBSCT after Mel200 treatment were performed in 72 patients between January 2006 and December 2009 at our institution. Patients received either single-dose pegfilgrastim (n = 46; 50%), or daily filgrastim (n = 46; 50%) after APBSCT (median duration of filgrastim use, 9 days; range, 3-14 days). Duration of neutropenia grade IV was shorter with pegfilgrastim compared with filgrastim (median, 5 days (range, 3-14 days) versus 6 days (range, 3-9 days), p = 0.0079). The length of hospitalization differed significantly (pegfilgrastim (median, 14.5 days; range, 11-47 days) versus filgrastim (median, 15.5 days; range, 12-64 days), p = 0.024). Pegfilgrastim-treated patients had less red blood cell transfusions (median, 0 transfusions (range, 0-10) versus 0.5 transfusions (range, 0-9), p = 0.00065). Pegfilgrastim was associated with reduced cost of the treatment procedure compared with filgrastim (p = 0.031). Pegfilgrastim appears to be at least equivalent to filgrastim without additional expenditure in myeloma patients treated with Mel200 and APBSCT. |
| | |
Authors:
|
Panagiotis Samaras; Marcel Blickenstorfer; Raffaele Daniele Siciliano; Sarah R Haile; Elefteri M Buset; Ulf Petrausch; Axel Mischo; Hanspeter Honegger; Urs Schanz; Georg Stussi; Rolf A Stahel; Alexander Knuth; Frank Stenner-Liewen; Christoph Renner |
Publication Detail:
|
Type: Evaluation Studies; Journal Article Date: 2010-08-13 |
Journal Detail:
|
Title: Annals of hematology Volume: 90 ISSN: 1432-0584 ISO Abbreviation: Ann. Hematol. Publication Date: 2011 Jan |
Date Detail:
|
Created Date: 2011-01-03 Completed Date: 2011-01-28 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9107334 Medline TA: Ann Hematol Country: Germany |
Other Details:
|
Languages: eng Pagination: 89-94 Citation Subset: IM |
Affiliation:
|
Department of Oncology, University Hospital Zürich, Rämistrasse 100, 8091, Zürich, Switzerland. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Aged Antineoplastic Agents / therapeutic use Combined Modality Therapy Dosage Forms Dose-Response Relationship, Drug Female Filgrastim / therapeutic use* Hospitalization / statistics & numerical data Humans Length of Stay* / statistics & numerical data Male Melphalan / administration & dosage* Middle Aged Multiple Myeloma / therapy* Peripheral Blood Stem Cell Transplantation* / methods Time Factors Transplantation Conditioning* / methods, statistics & numerical data Transplantation, Autologous Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Antineoplastic Agents; 0/Dosage Forms; 0/pegfilgrastim; 121181-53-1/Filgrastim; 148-82-3/Melphalan |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: The role of routine imaging procedures in the detection of relapse of patients with Hodgkin lymphoma...
Next Document: GSEA-SNP identifies genes associated with Johne's disease in cattle.